Abstract
The blockage of the voltage dependent ion channel encoded by human ether-a-go-go related gene (hERG) may lead to drug-induced QT interval prolongation, which is a critical side-effect of non-cardiovasular therapeutic agents. Therefore, identification of potential hERG channel blockers at the early stage of drug discovery process will decrease the risk of cardiotoxicity-related attritions in the later and more expensive development stage. Computational approaches provide economic and efficient ways to evaluate the hERG liability for large-scale compound libraries. In this review, the structure of the hERG channel is briefly outlined first. Then, the latest developments in the computational predictions of hERG channel blockers and the theoretical studies on modeling hERG-blocker interactions are summarized. Finally, the challenges of developing reliable prediction models of hERG blockers, as well as the strategies for surmounting these challenges, are discussed.
Keywords: hERG, QT prolongation, ADME/T, QSAR, QSPR, homology modeling, pharmacophore modeling, molecular docking.
Current Topics in Medicinal Chemistry
Title:Recent Developments in Computational Prediction of hERG Blockage
Volume: 13 Issue: 11
Author(s): Sichao Wang, Youyong Li, Lei Xu, Dan Li and Tingjun Hou
Affiliation:
Keywords: hERG, QT prolongation, ADME/T, QSAR, QSPR, homology modeling, pharmacophore modeling, molecular docking.
Abstract: The blockage of the voltage dependent ion channel encoded by human ether-a-go-go related gene (hERG) may lead to drug-induced QT interval prolongation, which is a critical side-effect of non-cardiovasular therapeutic agents. Therefore, identification of potential hERG channel blockers at the early stage of drug discovery process will decrease the risk of cardiotoxicity-related attritions in the later and more expensive development stage. Computational approaches provide economic and efficient ways to evaluate the hERG liability for large-scale compound libraries. In this review, the structure of the hERG channel is briefly outlined first. Then, the latest developments in the computational predictions of hERG channel blockers and the theoretical studies on modeling hERG-blocker interactions are summarized. Finally, the challenges of developing reliable prediction models of hERG blockers, as well as the strategies for surmounting these challenges, are discussed.
Export Options
About this article
Cite this article as:
Wang Sichao, Li Youyong, Xu Lei, Li Dan and Hou Tingjun, Recent Developments in Computational Prediction of hERG Blockage, Current Topics in Medicinal Chemistry 2013; 13 (11) . https://dx.doi.org/10.2174/15680266113139990036
DOI https://dx.doi.org/10.2174/15680266113139990036 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
NADPH Oxidases in the Heart
Current Cardiology Reviews Post Cardiovascular Surgery Atrial Fibrillation. Biomarkers Determining Prognosis
Current Medicinal Chemistry Editorial (Thematic Issues: Pharmacological Mechanisms and Interventions in Ischemia/ Reperfusion-Induced Injury)
Current Pharmaceutical Design Antioxidants in Treating Pathologies Involving Oxidative Damage: An Update on Medicinal Chemistry and Biological Activity of Stobadine and Related Pyridoindoles
Current Medicinal Chemistry MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design COVID-19 Infection in Pregnancy: A Review
Infectious Disorders - Drug Targets Endogenous Cardiotonics: Search and Problems
Cardiovascular & Hematological Disorders-Drug Targets STABIL-study: The Course of Therapy, Safety and Pharmacokinetic Parameters of Conversion of Prograf® to Tacrolimus HEXAL®/Crilomus® in Renal Transplant Recipients – an Observational Study in Germany
Current Reviews in Clinical and Experimental Pharmacology Pituitary Dysfunction as a Cause of Cardiovascular Disease
Current Pharmaceutical Design A Review on Novel Ligand Targeted Delivery for Cardiovascular Disorder
Current Drug Delivery Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets A Review of Patents on Implantable Heart-Compression/Assist Devices and Systems
Recent Patents on Biomedical Engineering (Discontinued) Statins in the Prevention of Cardiovascular Events in Patients with Renal Failure
Cardiovascular & Hematological Disorders-Drug Targets Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy Inhibition of Drug Efflux in Mycobacteria with Phenothiazines and Other Putative Efflux Inhibitors
Recent Patents on Anti-Infective Drug Discovery Cardiac (myo)fibroblast: Novel Strategies for its Targeting Following Myocardial Infarction
Current Pharmaceutical Design Exercise and Ischemic Preconditioning
Current Cardiology Reviews Automated Planar Electrode Electrophysiology in Drug Discovery: Examples of the Use of QPatch in Basic Characterization and High Content Screening on Nav, KCa2.3, and Kv11.1 Channels
Combinatorial Chemistry & High Throughput Screening